为什么礼来的口服GLP-1数据促进了结构和美血清？

Obesity drug developers Structure Therapeutics (NASDAQ:GPCR) and Metsera (NASDAQ:MTSR) recorded sharp gains alongside Eli Lilly (NYSE:LLY) on Thursday after the Indiana-based pharma giant reported Phase 3 data for its oral GLP-1 agonist orforglipron in type 2 diabetes.

While LLY said that the once-daily pill hit the main goal related to a key diabetes marker called A1C in the study, its data in terms of a secondary endpoint linked to weight loss caught the attention of Wall Street.

Both Structure (NASDAQ:GPCR) and Metsera (NASDAQ:MTSR) own oral GLP-1 receptor agonists, which are currently undergoing mid-stage trials for patients with obesity and overweight with or without diabetes. Meanwhile, Viking Therapeutics (NASDAQ:VKTX), whose oral obesity drug VK2735—designed to target not only GLP-1 receptors but also GIP receptors in mid-stage development—traded flat.

Structure’s (NASDAQ:GPCR) once-daily therapy aleniglipron is set to generate topline data from its Phase 2b ACCESS and Phase 2 ACCESS II studies in Q4 2025. Multiple Phase 2b readouts for Metsera’s (NASDAQ:MTSR) monthly GLP-1 receptor agonist, MET-097i, are expected to arrive from mid-2025.

According to LLY, orforglipron caused up to 8% of weight loss on average in the 40-week global trial, a finding J.P. Morgan analyst Chris Schott cited as more or less comparable to the effects of rival Novo Nordisk’s (NVO) weight loss drug Wegovy and in line with Street forecasts.

Schott, with an overweight rating on LLY, also highlighted the trial's safety data, arguing that the drug's tolerability profile seemed manageable and there was no evidence to indicate incremental safety concerns.

Data “suggests to us a mid-teens % of weight loss from the phase 3 ATTAIN-1 study for obesity is highly probable, given its longer study length,” Citi analyst Geoff Meacham added with a Buy recommendation on LLY, referring to the drug’s next readout expected later this year.